How to buy TransCode Therapeutics stock (TransCode Therapeutics Inc)

TransCode Therapeutics is a biotechnology business based in the US. TransCode Therapeutics shares (RNAZ) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.52 – a decrease of 10.2% over the previous week. TransCode Therapeutics employs 10 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Transcode Therapeutics stock

Buy TransCode Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

TransCode Therapeutics stock price (NASDAQ: RNAZ)

Use our graph to track the performance of RNAZ stocks over time.

TransCode Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$3.52
52-week range	$3.21 - $264.00
50-day moving average more info button	$14.43
200-day moving average more info button	$20.70
Wall St. target price	$20.00
PE ratio more info button	0.0007
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$5,571.72

Is it a good time to buy TransCode Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

TransCode Therapeutics price performance over time

Historical closes compared with the close of $3.58 from 2024-12-23

1 week (2024-12-18)	-8.67%
1 month (2024-11-25)	940.70%
3 months (2024-09-25)	451.62%
6 months (2024-06-25)	244.23%

1 year (2023-12-22)	1,794.18%
2 years (2022-12-23)	-99.96%
3 years (2021-12-23)	70752
5 years (2019-12-21)	N/A

Is TransCode Therapeutics stock undervalued or overvalued?

Valuing TransCode Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of TransCode Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

TransCode Therapeutics's P/E ratio

TransCode Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, TransCode Therapeutics shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, TransCode Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

• Catalyst Pharmaceuticals (CPRX.US): 18.09
• BioDelivery Sciences International (BDSI.US): 6.82
• Trillium Therapeutics (TRIL.US): 0.00

TransCode Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-207.95%
Return on equity TTM	-1048.7%
Profit margin	0%
Book value	$2.62
Market Capitalization more info button	$2.7 million

TTM: trailing 12 months

TransCode Therapeutics share dividends

We're not expecting TransCode Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Have TransCode Therapeutics's shares ever split?

TransCode Therapeutics's shares were split on a 1:33 basis on 3 December 2024 . So if you had owned 33 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TransCode Therapeutics shares – just the quantity. However, indirectly, the new 3200% higher share price could have impacted the market appetite for TransCode Therapeutics shares which in turn could have impacted TransCode Therapeutics's share price.

TransCode Therapeutics share price volatility

Over the last 12 months, TransCode Therapeutics's shares have ranged in value from as little as $3.21 up to $264. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TransCode Therapeutics's is 0.647. This would suggest that TransCode Therapeutics's shares are less volatile than average (for this exchange).

To put TransCode Therapeutics's beta into context you can compare it against those of similar companies.

• Catalyst Pharmaceuticals (CPRX.US): 0.755
• BioDelivery Sciences International (BDSI.US): 0.5551
• Trillium Therapeutics (TRIL.US): 1.9046

TransCode Therapeutics overview

TransCode Therapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D.

Frequently asked questions

What percentage of TransCode Therapeutics is owned by insiders or institutions?
Currently 0.009% of TransCode Therapeutics shares are held by insiders and 1.994% by institutions. How many people work for TransCode Therapeutics?
Latest data suggests 10 work at TransCode Therapeutics. When does the fiscal year end for TransCode Therapeutics?
TransCode Therapeutics's fiscal year ends in December. Where is TransCode Therapeutics based?
TransCode Therapeutics's address is: 6 Liberty Square, Boston, MA, United States, 02109 What is TransCode Therapeutics's ISIN number?
TransCode Therapeutics's international securities identification number is: US89357L1052